Orelabrutinib for relapsed or hard-to-treat AIHA
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a targeted pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that has come back or not responded to standard treatments. It may help control your immune system's attack on your red blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of AIHA called warm AIHA (or Evans syndrome) or cold agglutinin disease.
- Your hemoglobin must be 100 g/L or lower, or you must have symptoms like cold-induced color changes in fingers or toes.
- Standard treatments (steroids for warm AIHA, rituximab for cold agglutinin disease) must have failed or not been an option for you.
- You cannot have taken a BTK inhibitor before.
- You must be able to stop other AIHA medications (like steroids, cyclosporine, or danazol) before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
This trial tests an oral medication (rilzabrutinib) against a placebo for people with warm autoimmune hemolytic anemia (wAIHA). It aims to see if the drug can help control the disease with fewer side effects than current treatments.
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
This trial tests a new targeted drug (orelabrutinib) combined with standard therapy for people with a specific genetic type of DLBCL called MCD subtype. After initial treatment, you would continue on the targeted drug alone to help prevent the cancer from coming back.
Hear when a new Autoimmune Hemolytic Anemia (AIHA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.